Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia

被引：0
|
作者：
Cesar Solano, Julio [1 ]
机构：
[1] Pontificia Univ Javeriana, Hosp San Ignacio, Bogota, Colombia
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2020年 / 26卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
370
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [1] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor
    Bahlis, Nizar J.
    Duggan, Peter
    Alonso, Rafael
    Lahuerta, Juan Jose
    Valeri, Antonio
    Neri, Paola
    Tay, Jason
    Martinez-Lopez, Joaquin
    [J]. BLOOD, 2016, 128 (22)
  • [2] Clinical Efficacy of a Bortezomib, Cyclophosphamide and Dexamethasone Compared with Bortezomib, Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Moon, Joon Ho
    Sohn, Sang Kyun
    Jung, Sung-Hoon
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    [J]. BLOOD, 2011, 118 (21) : 815 - 815
  • [3] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Figueiredo, Amarilis
    Atkins, Harold
    Mallick, Ranjeeta
    Kekre, Natasha
    Kew, Andrea
    McCurdy, Arleigh
    [J]. BLOOD, 2016, 128 (22)
  • [4] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    [J]. BLOOD, 2019, 134
  • [5] Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
    Kaufman, Jonathan L.
    Gleason, Charise
    Heffner, Leonard
    Lonial, Sagar
    [J]. BLOOD, 2007, 110 (11) : 1055A - 1055A
  • [6] Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
    Uttervall, Katarina
    Bruchfeld, Johanna Borg
    Gran, Charlotte
    Walinder, Goran
    Mansson, Robert
    Lund, Johan
    Gahrton, Gosta
    Alici, Evren
    Nahi, Hareth
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (03) : 247 - 254
  • [7] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Lavoie-Gagnon, Claudie
    St-Gelais, Jonathan
    Adam, Jean-Philippe
    Viens, Daniel
    Gagne, Felixe
    Decarie, Yann
    Lemieux-Blanchard, Emilie
    [J]. BLOOD, 2017, 130
  • [8] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
    Tsukada, Nobuhiro
    Ikeda, Masahiro
    Shingaki, Sumito
    Miyazaki, Kanji
    Meshitsuka, Sosuke
    Abe, Yu
    Yoshiki, Yumiko
    Suzuki, Kenshi
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
  • [9] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Venner, Christopher P.
    Belch, Andrew
    Sandhu, Irwindeep
    Nikitina, Tatiana
    Hewitt, Joanne D.
    Duggan, Peter
    Neri, Paola
    Rashid-Kolvear, Fariborz
    Bahlis, Nizar J.
    [J]. BLOOD, 2015, 126 (23)
  • [10] Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
    Figueiredo, A.
    Atkins, H.
    Mallick, R.
    Kekre, N.
    Kew, A.
    McCurdy, A.
    [J]. CURRENT ONCOLOGY, 2020, 27 (02) : E81 - E85
12345